SCHEMBL17239603

SCHEMBL17239603

COC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)c(C)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
MAPT P10636 4/20 0.38
NPSR1 Q6W5P4 4/20 0.38
ALDH1A1 P00352 2/20 0.38
HTT P42858 2/20 0.38
TP53 P04637 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
UCHL1 P09936 1/20 0.36
GAA P10253 2/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ABL1 P00519 1/20 0.34
PTGS2 P35354 1/20 0.33
TSHR P16473 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
HIF1A Q16665 1/20 0.32
DGAT1 O75907 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2844695 0.89 MEN1 (0.39) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL1918526 0.87 UCHL1 (0.36) MAPTALDH1A1HPGDHSD17B10UCHL1
SCHEMBL17187034 0.85 GAA (0.39) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL24468336 0.85 GAA (0.43) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL17239436 0.85 GAA (0.43) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL17201292 0.84 CA12 (0.41) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL17239587 0.84 TSHR (0.35) ALDH1A1HTTTP53LMNASMN1; SMN2
SCHEMBL252045 0.83 GAA (0.41) KMT2AMAPTALDH1A1HTTHPGD
SCHEMBL19946099 0.83 GAA (0.38) MEN1KMT2AMAPTNPSR1ALDH1A1
SCHEMBL16113731 0.83 UCHL1 (0.34) MAPTALDH1A1HPGDHSD17B10UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3140298-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS Pfizer Inc. (US) 2017-03-15 EP disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
WO-2015170218-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS TPM3, MUSK, TPM4 MEN1 3887/4885KMT2A 3210/4885MAPT 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.